Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer
Clinical Lung Cancer · 2024
DOI: 10.1016/j.cllc.2024.06.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Arpeet T Shah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Healthcare, Castro Valley, CA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutrophils, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCRR NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND: Prior research in non-small cell lung cancer (NSCLC) has shown that tumors with specific driver mutations may be less likely to respond to immune checkpoint inhibitors (ICI). In this analysis, we evaluated the characteristics of patients with durable clinical benefit (DCB) to ICI compared to those with no durable clinical benefit (NDB), with emphasis on the role of molecular alterations in EGFR, ALK, and ROS1 and pretreatment neutrophil-to-lymphocyte ratio (NLR). METHODS: We retrospectively collected clinical characteristics and outcomes for patients who initiated ICI monotherapy for advanced NSCLC at Stanford University between April 2015 and May 2018. Patients were classified as having DCB if time on ICI therapy was greater than or equal to 180 days, or NDB if less than 180 days. Outcomes included best radiographic benefit while on ICI and survival from time of ICI initiation. RESULTS: Of 123 patients treated with ICI for NSCLC, 28 patients had DCB (23%), while 95 had NDB (77%). Median overall survival from initiation of ICI in the 33 patients with molecular alterations in EGFR (n = 31), ALK, or ROS1 and NLR of 5.9 or higher was 2.0 months, compared to 8.1 months in patients with these genomic alterations and NLR less than 5.9. Median overall survival in patients without alterations in EGFR, ALK, or ROS1 and NLR of 5.9 or higher was 4.3 months, compared to 12.1 months in patients with NLR less than 5.9 (P = .023). CONCLUSIONS: Elevation in pretreatment NLR was associated with significantly lower overall median survival from initiation of ICI, particularly when in combination with NSCLC with alterations in EGFR, ALK, or ROS1. This finding could influence clinical practice as NLR is readily available through routine blood testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stanford Healthcare, Castro Valley, CA.
- Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.
- Department of Hematology/Oncology, Fox Chase Cancer Center, Temple University, Philadelphia, PA.
- Department of Medicine, Division of Oncology, Stanford University, Stanford, CA. Electronic address: jwneal@stanford.edu.
Förderung
- NCI NIH HHS
- NCRR NIH HHS
- National Cancer Institute
Zitieren
APA
Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., & Neal, J. W. (2024). Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.06.006
Vancouver
Shah AT, Blanchard I, Padda SK, Wakelee HA, Neal JW. Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.06.006
BibTeX
@article{Shah2024,
author = {Shah, Arpeet T and Blanchard, Isabelle and Padda, Sukhmani K and Wakelee, Heather A and Neal, Joel W},
title = {Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer},
journal = {Clinical Lung Cancer},
year = {2024},
doi = {10.1016/j.cllc.2024.06.006}
}
EUVIMED